Premium
Multiplex gene‐panel testing for lung cancer patients
Author(s) -
Yatabe Yasushi,
Sunami Kuniko,
Goto Koichi,
Nishio Kazuto,
Aragane Naoko,
Ikeda Sadakatsu,
Inoue Akira,
Kinoshita Ichiro,
Kimura Hideharu,
Sakamoto Tomohiro,
Satouchi Miyako,
Shimizu Junichi,
Tsuta Koji,
Toyooka Shinichi,
Nishino Kazumi,
Hatanaka Yutaka,
Matsumoto Shingo,
Mikubo Masashi,
Yokose Tomoyuki,
DosakaAkita Hirotoshi
Publication year - 2020
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.13023
Subject(s) - lung cancer , reimbursement , medicine , genetic testing , precision medicine , cancer , multiplex , oncology , bioinformatics , pathology , computational biology , health care , biology , economics , economic growth
The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene‐panel tests using next‐generation sequencing (NGS) techniques being introduced into clinical practice. Among the three tests, the Oncomine CDx Target test was approved under the category of regular molecular testing for lung cancer, which meant that this test could be used to select patients for molecularly targeted drugs. Conversely, the other two tests, NCC OncoPanel and FoundationOne CDx, were assigned to be used under the National Cancer Genome Medicine Network, and implementation was restricted to patients for whom standard treatment was completed or expected to be completed. These NGS tests can detect a series of genetic alterations in individual tumors, which further promotes the development of therapeutic agents and elucidates molecular pathways. The NGS tests require appropriate tissue size and tumor cell content, which can be accessed only by pathologists. In this report, we review the current reimbursement schema in our national healthcare policy and the requirements of the specimens for NGS testing based on the recently published ‘Guidance of Gene‐panel Testing Using Next‐Generation Sequencers for Lung Cancer’, by the Japanese Society of Lung Cancer.